



Model List of Essential Medicines

Medicines for COVID-19

Section	Indications
Medicines for COVID-19 Refer to WHO living guidelines	COVID-19

Abacavir

Section	Indications
Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors Oral > Solid: 300 mg tablet (as sulfate)	Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Abacavir + lamivudine

Section	Indications
Fixed-dose combinations of antiretrovirals Oral > Solid: 120 mg (as sulfate) + 60 mg tablet (dispersible, scored)	Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Abacavir + lamivudine + lopinavir + ritonavir

Section	Indications
Fixed-dose combinations of antiretrovirals Oral > Solid: 30 mg + 15 mg + 40 mg + 10 mg capsule containing oral granules	Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Aciclovir

Section	Indications
Antiherpes medicines Parenteral > General injections > IV: 250 mg in vial powder for injection (as sodium salt) Oral > Liquid: 200 mg per 5 mL Oral > Solid: 200 mg tablet	Zoster Varicella Herpes simplex infections

Albendazole

Section	Indications
Intestinal anthelmintics Oral > Solid > tablet: 400 mg (chewable, scored)	Echinococcosis
Oral > Solid > tablet: 400 mg (chewable, scored))	Ascariasis
	Enterobiasis
	Trichuriasis
	Hookworm diseases
	Cysticercosis
Cysticidal medicines Oral > Solid > tablet: 400 mg (chewable, scored); 200 mg (chewable)	Other specified echinococcosis
	Cysticercosis of central nervous system
Antifilarials Oral > Solid > tablet: 400 mg (chewable, scored)	Filariasis

Amikacin

Section	Indications
Access group antibiotics Parenteral > General injections > unspecified: 250 mg per mL in 2 mL vial (as sulfate)	First choice co-prescribed with cefotaxime Acute pyelonephritis (severe)
	co-prescribed with ceftriaxone Acute pyelonephritis (severe)
Antituberculosis medicines Parenteral > General injections > unspecified: 250 mg per mL in 2 mL vial (as sulfate)	Second choice co-prescribed with cloxacillin Sepsis without septic shock Multi-drug resistant Mycobacterium tuberculosis

Amodiaquine

Section	Indications
Antimalarial medicines > For curative treatment Oral > Solid: 153 mg (as hydrochloride); 200 mg (as hydrochloride)	Malaria due to Plasmodium falciparum Malaria due to Plasmodium vivax

Amodiaquine + sulfadoxine + pyrimethamine

Section	Indications
<p>Antimalarial medicines > For chemoprevention</p> <p>Oral > Solid: 76.5 mg (as hydrochloride) [3] + 250 mg + 12.5 mg [1] dispersible tablets in co-package; 153 mg (as hydrochloride) [3] + 500 mg + 25 mg [1] dispersible tablets in co-package</p>	Malaria

Amoxicillin

Section	Indications
<p>Access group antibiotics</p> <p>Oral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral liquid; 250 mg per 5 mL (anhydrous) powder for oral liquid</p> <p>Oral > Solid: 250 mg (anhydrous) capsule or tablet; 500 mg (anhydrous) capsule or tablet</p> <p>Oral > Liquid: 125 mg per 5 mL (as trihydrate) powder for oral liquid; 250 mg per 5 mL (as trihydrate) powder for oral liquid</p> <p>Oral > Solid: 250 mg (as trihydrate); 500 mg (as trihydrate)</p> <p>Parenteral > General injections > unspecified: 250 mg in vial (as sodium) powder for injection; 500 mg in vial (as sodium) powder for injection; 1 g in vial (as sodium) powder for injection</p>	<p>First choice</p> <p>Chronic obstructive pulmonary disease with acute exacerbation</p> <p>co-prescribed with gentamicin</p> <p>Sepsis without septic shock</p> <p>Other indications</p> <p>Bacterial infection of unspecified site</p> <p>Infectious cystitis</p>

Amoxicillin + clavulanic acid

Section	Indications
Access group antibiotics Parenteral > General injections > IV: 500 mg (as sodium salt) + 100 mg (as potassium salt) powder for injection; 1000 mg (as sodium salt) + 200 mg (as potassium salt) powder for injection Oral > Solid: 500 mg (as trihydrate) + 125 mg (as potassium salt) Oral > Liquid: 250 mg + 62.5 mg per 5 mL powder for oral liquid; 125 mg + 31.25 mg per 5 mL powder for oral liquid Oral > Solid: 500 mg + 125 mg tablet Oral > Liquid: 125 mg (as trihydrate) + 31.25 mg (as potassium salt) powder for oral liquid; 250 mg (as trihydrate) + 62.5 mg (as potassium salt) powder for oral liquid Oral > Solid: 500 mg (as trihydrate) + 125 mg (as potassium salt); 875 mg (as trihydrate) + 125 mg (as potassium salt) Oral > Solid > dispersible tablet: 200 mg (as trihydrate) + 28.5 mg (as potassium salt); 250 mg (as trihydrate) + 62.5 mg (as potassium salt)	First choice Infectious cystitis Chronic obstructive pulmonary disease with acute exacerbation Other indications Bacterial infection of unspecified site
Antituberculosis medicines Oral > Liquid: 250 mg (as trihydrate) + 62.5 mg per 5 mL (as potassium salt) powder for oral liquid Oral > Solid: 500 mg (as trihydrate) + 125 mg (as potassium salt)	Multi-drug resistant Mycobacterium tuberculosis

Amphotericin B

Section	Indications
Antifungal medicines Parenteral > General injections > IV: 50 mg in vial powder for injection (liposomal complex); 50 mg in vial powder for injection (as sodium deoxycholate)	Blastomycosis Aspergillosis Cryptococcosis Candidosis Coccidioidomycosis Histoplasmosis Sporotrichosis
Antileishmaniasis medicines Parenteral > General injections > IV: 50 mg in vial powder for injection (liposomal complex); 50 mg in vial powder for injection (as sodium deoxycholate)	Visceral leishmaniasis

Ampicillin

Section	Indications
Access group antibiotics	
Parenteral > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection; 1 g in vial (as sodium salt) powder for injection	First choice co-prescribed with gentamicin
Oral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral suspension	Peritoneal abscess (severe) co-prescribed with gentamicin
Oral > Solid: 250 mg (anhydrous); 500 mg (anhydrous)	Sepsis without septic shock co-prescribed with gentamicin
	Peritoneal abscess (mild-moderate) co-prescribed with gentamicin
	Peritonitis (severe) co-prescribed with gentamicin
	Acute malnutrition in infants, children or adolescents (complicated) [children] co-prescribed with gentamicin
	Peritonitis (mild-moderate) co-prescribed with gentamicin
	Bacterial pneumonia (Community-acquired pneumonia - severe) [children]
Second choice	
	Bacterial meningitis
Other indications	
	Bacterial infection of unspecified site

Anidulafungin

Section	Indications
Antifungal medicines	Therapeutic equivalent to micafungin for Systemic or invasive candidosis

Ansuvinimab

Section	Indications
Medicines for Ebola virus disease	Ebola virus disease
Parenteral > General injections > IV: 400 mg powder for injection	

Artemether

Section	Indications
Antimalarial medicines > For curative treatment Parenteral > General injections > IM: 80 mg per mL in 1 mL ampoule (oily injection)	Malaria due to Plasmodium falciparum Malaria due to Plasmodium vivax

Artemether + lumefantrine

Section	Indications
Antimalarial medicines > For curative treatment Oral > Solid: 20 mg + 120 mg tablet; 20 mg + 120 mg dispersible tablet	Malaria due to Plasmodium falciparum Malaria due to Plasmodium vivax

Artesunate

Section	Indications
Antimalarial medicines > For curative treatment Parenteral > General injections > IV: 60 mg in ampoule containing anhydrous artesunic acid with a separate ampoule of 5% sodium bicarbonate solution	Malaria due to Plasmodium falciparum Malaria due to Plasmodium vivax
Oral > Solid: 50 mg tablet	
Local > Rectal > Other: 50 mg capsules; 200 mg capsules; 100 mg capsules	

Artesunate + amodiaquine

Section	Indications
Antimalarial medicines > For curative treatment Oral > Solid: 25 mg + 67.5 mg tablet; 50 mg + 135 mg tablet; 100 mg + 270 mg tablet	Malaria due to Plasmodium falciparum Malaria due to Plasmodium vivax

Artesunate + mefloquine

Section	Indications
Antimalarial medicines > For curative treatment Oral > Solid: 25 mg + 55 mg tablet; 100 mg + 220 mg tablet	Malaria due to Plasmodium falciparum Malaria due to Plasmodium vivax

Artesunate + pyronaridine tetraphosphate

Section	Indications
Antimalarial medicines > For curative treatment Oral > Solid: 60 mg + 180 mg tablet; 20 mg + 60 mg granules	Malaria due to Plasmodium falciparum Malaria due to Plasmodium vivax

Atazanavir

Section	Indications
Antiretrovirals > Protease inhibitors Oral > Solid: 100 mg (as sulfate); 300 mg (as sulfate)	Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Atazanavir + ritonavir

Section	Indications
Antiretrovirals > Protease inhibitors Oral > Solid: 300 mg (as sulfate) + 100 mg tablet (heat stable)	Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Atoltivimab + maftivimab + odesivimab

Section	Indications
Medicines for Ebola virus disease Parenteral > General injections > IV: 241.7 mg + 241.7 mg + 241.7 mg in 14.5 mL vial	Ebola virus disease

Azithromycin

Section	Indications
Watch group antibiotics	First choice
Oral > Liquid: 200 mg per 5 mL oral liquid	co-prescribed with ceftriaxone
Oral > Solid: 250 mg (anhydrous) capsule; 500 mg (anhydrous) capsule	Gonococcal infection
	Second choice
	co-prescribed with cefixime
	Gonococcal infection

Aztreonam

Section	Indications
Reserve group antibiotics	Other specified bacterial diseases

Bedaquiline

Section	Indications
Antituberculosis medicines Oral > Solid: 100 mg tablet; 20 mg tablet	Multi-drug resistant Mycobacterium tuberculosis

Benzathine benzylpenicillin

Section	Indications
Access group antibiotics Parenteral > General injections > IM: 900 mg in vial benzylpenicillin powder for injection (= 1.2 million IU); 1.44 g in vial benzylpenicillin powder for injection (= 2.4 million IU)	First choice Syphilis Congenital syphilis [children]
	Other indications Bacterial infection of unspecified site

Benznidazole

Section	Indications
American trypanosomiasis Oral > Solid > tablet: 100 mg (scored); 50 mg (scored); 12.5 mg	Chagas disease

Benzylpenicillin

Section	Indications
Access group antibiotics Parenteral > General injections > unspecified: 600 mg in vial powder for injection (=1 million IU as sodium or potassium salt); 3 g in vial powder for injection (=5 million IU as sodium or potassium salt) Parenteral > General injections > unspecified: 600 mg in vial powder for injection (= 1 million IU as sodium or potassium salt); 3 g in vial powder for injection (= 5 million IU as sodium or potassium salt)	First choice Congenital syphilis [children] Syphilis co-prescribed with gentamicin Sepsis without septic shock co-prescribed with gentamicin Acute malnutrition in infants, children or adolescents (complicated) [children] co-prescribed with gentamicin Bacterial pneumonia (Community-acquired pneumonia - severe) [children] Second choice Bacterial meningitis
	Other indications Bacterial infection of unspecified site

Capreomycin

Section	Indications
Antituberculosis medicines Parenteral > General injections > IV: 1000 mg powder for injection (vial)	Multi-drug resistant Mycobacterium tuberculosis

Caspofungin

Section	Indications
Antifungal medicines	Therapeutic equivalent to micafungin for Systemic or invasive candidosis

Cefalexin

Section	Indications
Access group antibiotics	
Oral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral liquid; 250 mg per 5 mL (anhydrous) powder for oral liquid	Second choice Chronic obstructive pulmonary disease with acute exacerbation
Oral > Solid: 250 mg (as monohydrate)	Other indications
Oral > Solid: 250 mg (as monohydrate); 500 mg (as monohydrate)	Bacterial infection of unspecified site

Cefazolin

Section	Indications
Access group antibiotics	
Parenteral > General injections > unspecified: 1 g in vial (as sodium salt) powder for injection	First choice Other specified prophylactic measures co-prescribed with metronidazole
	Other specified prophylactic measures
	Second choice Osteomyelitis or osteitis
	Bacterial infection of joint
	Other indications
	Surgical site infection

Cefepime

Section	Indications
Watch group antibiotics	Other specified bacterial diseases

Cefixime

Section	Indications
<p>Watch group antibiotics</p> <p>Oral > Liquid: 100 mg per 5 mL powder for oral liquid</p> <p>Oral > Solid: 200 mg (as trihydrate); 400 mg (as trihydrate)</p>	<p>Second choice</p> <p>Infectious gastroenteritis or colitis without specification of infectious agent</p> <p>co-prescribed with azithromycin</p> <p>Gonococcal infection</p>

Cefotaxime

Section	Indications
<p>Watch group antibiotics</p> <p>Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt)</p>	Bacterial infection of unspecified site

Ceftaroline

Section	Indications
<p>Reserve group antibiotics</p> <p>Parenteral > General injections > IV: 400 mg in vial (as fosamil) powder for injection; 600 mg in vial (as fosamil) powder for injection</p>	Other specified bacterial diseases

Ceftazidime

Section	Indications
<p>Watch group antibiotics</p> <p>Parenteral > General injections > unspecified: 250 mg in vial (as pentahydrate) powder for injection; 1 g in vial (as pentahydrate) powder for injection</p>	<p>First choice</p> <p>co-prescribed with vancomycin</p> <p>Endophthalmitis</p> <p>Other indications</p> <p>Pseudomonas aeruginosa resistant to other antibiotic</p>

Ceftazidime + avibactam

Section	Indications
<p>Reserve group antibiotics</p> <p>Parenteral > General injections > IV: 2 g in vial + 0.5 g in vial powder for injection</p>	<p>Carbapenem-resistant Pseudomonas aeruginosa</p> <p>Carbapenem resistant Enterobacteriales</p>

Ceftolozane + tazobactam

Section	Indications
Reserve group antibiotics Parenteral > General injections > IV: 1 g + 0.5 g powder for injection	Carbapenem-resistant <i>Pseudomonas aeruginosa</i>

Ceftriaxone

Section	Indications
Watch group antibiotics Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt)	First choice co-prescribed with metronidazole
Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt)	Necrotising fasciitis
	Other indications
	Bacterial infection of unspecified site

Cefuroxime

Section	Indications
Watch group antibiotics Parenteral > General injections > IV: 250 mg in vial (as sodium salt) powder for injection; 750 mg in vial (as sodium salt) powder for injection; 1.5 g in vial (as sodium salt) powder for injection	Second choice Other specified prophylactic measures

Chloramphenicol

Section	Indications
Access group antibiotics Parenteral > General injections > IV: 1 g in vial powder for injection (sodium succinate) Parenteral > General injections > IM: 500 mg in 2 mL ampoule oily suspension for injection Oral > Liquid: 150 mg per 5 mL (as palmitate) Oral > Solid: 250 mg capsule	Bacterial infection of unspecified site

Chloroquine

Section	Indications
Antimalarial medicines > For chemoprevention	Malaria due to <i>Plasmodium falciparum</i>
Oral > Liquid: 50 mg per 5 mL syrup (as phosphate or sulfate)	Malaria due to <i>Plasmodium vivax</i>
Oral > Solid: 150 mg tablet (as phosphate or sulfate)	Malaria due to <i>Plasmodium ovale</i>
Antimalarial medicines > For curative treatment	Malaria due to <i>Plasmodium falciparum</i>
Parenteral > General injections > IV: 40 mg per mL in 5 mL ampoule (as hydrochloride, phosphate or sulfate)	Malaria due to <i>Plasmodium vivax</i>
Oral > Liquid: 50 mg per 5 mL syrup (as phosphate or sulfate)	
Oral > Solid: 150 mg tablet (as phosphate or sulfate); 100 mg tablet (as phosphate or sulfate)	

Ciprofloxacin

Section	Indications
Watch group antibiotics	First choice
Parenteral > General injections > IV: 2 mg per mL (as hydrate)	Inflammatory and other diseases of prostate (mild to moderate)
Oral > Liquid: 250 mg per 5 mL (anhydrous)	Other indications
Oral > Solid: 250 mg (as hydrochloride)	Bacterial infection of unspecified site
Oral > Solid: 250 mg (as hydrochloride); 500 mg (as hydrochloride)	

Clindamycin

Section	Indications
Access group antibiotics	Bacterial infection of unspecified site
Oral > Liquid: 75 mg per 5 mL (as palmitate hydrochloride)	
Oral > Solid: 150 mg (as hydrochloride) capsule	
Parenteral > General injections > unspecified: 150 mg per mL (as phosphate) injection	

Clofazimine

Section	Indications
Antituberculosis medicines	Multi-drug resistant <i>Mycobacterium tuberculosis</i>
Oral > Solid: 100 mg; 50 mg	
Antileprosy medicines	Leprosy
Oral > Solid: 100 mg; 50 mg	

Clotrimazole

Section	Indications
Antifungal medicines Local > Topical > Other: 1% vaginal cream; 10% vaginal cream; 100 mg vaginal tablet; 500 mg vaginal tablet	Vulvovaginal candidosis

Cloxacillin

Section	Indications
Access group antibiotics Oral > Liquid: 125 mg per 5 mL (as sodium salt) powder for oral liquid Oral > Solid: 500 mg (as sodium salt) capsule; 1 g (as sodium salt) capsule Parenteral > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection	Bacterial infection of unspecified site

Cobicistat + elvitegravir + emtricitabine + tenofovir disoproxil fumarate

Section	Indications
Fixed-dose combinations of antiretrovirals Oral > Solid: 150 mg + 150 mg + 200 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)	Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Cobicistat + elvitegravir + emtricitabine+ tenofovir alafenamide

Section	Indications
Fixed-dose combinations of antiretrovirals Oral > Solid: 150 mg + 150 mg + 200 mg + 10 mg	Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Colistin (injection)

Section	Indications
Reserve group antibiotics Parenteral > General injections > unspecified: 1 million IU in vial (as colistemethate sodium)	Other specified bacterial diseases

Cycloserine

Section	Indications
Antituberculosis medicines Oral > Solid: 250 mg; 125 mg	Multi-drug resistant Mycobacterium tuberculosis

Daclatasvir

Section	Indications
Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations Oral > Solid: 30 mg tablet (as hydrochloride); 60 mg tablet (as hydrochloride)	Chronic hepatitis C

Daclatasvir + sofosbuvir

Section	Indications
Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations Oral > Solid: 60 mg + 400 mg	Chronic hepatitis C

Dapsone

Section	Indications
Antileprosy medicines Oral > Solid: 100 mg tablet; 50 mg tablet; 25 mg tablet	Leprosy

Daptomycin

Section	Indications
Reserve group antibiotics Parenteral > General injections > IV: 350 mg in vial powder for injection; 500 mg in vial powder for injection	Other specified bacterial diseases

Darunavir

Section	Indications
Antiretrovirals > Protease inhibitors Oral > Solid: 75 mg; 400 mg; 600 mg; 800 mg	Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Dasabuvir

Section	Indications
Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations Oral > Solid: 250 mg tablet	Chronic hepatitis C

Delafloxacin

Section	Indications
<p>Watch group antibiotics Parenteral > General injections > IV: 300 mg lyophilized powder for injection Oral > Solid: 450 mg</p>	Methicillin resistant <i>Staphylococcus aureus</i>

Delamanid

Section	Indications
<p>Antituberculosis medicines Oral > Solid: 50 mg tablet; 25 mg tablet (dispersible)</p>	Multi-drug resistant <i>Mycobacterium tuberculosis</i>

Didanosine

Section	Indications
<p>Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors Oral > Liquid: 100 mg buffered powder for oral solution; 167 mg buffered powder for oral solution; 250 mg buffered powder for oral solution Oral > Solid: 25 mg buffered chewable dispersible tablet; 50 mg buffered chewable dispersible tablet; 100 mg buffered chewable dispersible tablet; 150 mg buffered chewable dispersible tablet; 200 mg buffered chewable dispersible tablet; 125 mg unbuffered enteric coated capsule; 200 mg unbuffered enteric coated capsule; 250 mg unbuffered enteric coated capsule; 400 mg unbuffered enteric coated capsule</p>	Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Diethylcarbamazine

Section	Indications
<p>Antifilarials Oral > Solid: 50 mg tablet (dihydrogen citrate); 100 mg tablet (dihydrogen citrate)</p>	Lymphatic filariasis

Dihydroartemisinin + piperaquine phosphate

Section	Indications
<p>Antimalarial medicines > For curative treatment Oral > Solid: 40 mg + 320 mg tablet; 20 mg + 160 mg tablet</p>	Malaria due to <i>Plasmodium falciparum</i> Malaria due to <i>Plasmodium vivax</i>

Diloxanide

Section	Indications
Antiamoebic and antigiardiasis medicines Oral > Solid: 500 mg (furoate)	Amoebiasis

Dolutegravir

Section	Indications
Antiretrovirals > Integrase inhibitors Oral > Solid: 50 mg tablet; 10 mg tablet (dispersible, scored)	Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Dolutegravir + lamivudine + tenofovir

Section	Indications
Fixed-dose combinations of antiretrovirals Oral > Solid: 50 mg + 300 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)	Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Doxycycline

Section	Indications
Access group antibiotics Oral > Solid: 100 mg (as hyclate) Parenteral > General injections > unspecified: 100 mg in vial powder for injection Oral > Liquid: 25 mg per 5 mL (anhydrous); 50 mg per 5 mL (anhydrous) Oral > Solid: 100 mg (as hyclate); 50 mg (as hyclate)	<p>First choice</p> <p>Chlamydia trachomatis</p> <p>Second choice</p> <p>Chronic obstructive pulmonary disease with acute exacerbation</p> <p>Other indications</p> <p>Bacterial infection of unspecified site</p> <p>Malaria due to Plasmodium falciparum</p> <p>Malaria due to Plasmodium falciparum</p>
Antimalarial medicines > For curative treatment Oral > Solid: 100 mg (hydrochloride or hyclate); 100 mg dispersible tablet (as monohydrate)	
Antimalarial medicines > For chemoprevention Oral > Solid: 100 mg (hydrochloride or hyclate)	

Efavirenz

Section	Indications
Antiretrovirals > Non-nucleoside reverse transcriptase inhibitors Oral > Solid: 600 mg tablet	Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Efavirenz + emtricitabine + tenofovir

Section	Indications
Fixed-dose combinations of antiretrovirals Oral > Solid: 600 mg + 200 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)	Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Efavirenz + lamivudine + tenofovir

Section	Indications
Fixed-dose combinations of antiretrovirals Oral > Solid: 400 mg + 300 mg + 300 mg (tenofovir disoproxil fumarate, equivalent to 245 mg tenofovir disoproxil)	Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified Therapeutic equivalent to efavirenz + emtricitabine + tenofovir for Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Eflornithine

Section	Indications
Medicines for the treatment of 2nd stage African trypanosomiasis Parenteral > General injections > IV: 200 mg per mL in 50 mL bottle (hydrochloride)	African trypanosomiasis

Elbasvir + grazoprevir

Section	Indications
Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations Oral > Solid: 50 mg + 100 mg	Chronic hepatitis C

Emtricitabine

Section	Indications
Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors Oral > Liquid: 10 mg per mL Oral > Solid: 200 mg	Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Emtricitabine + rilpivirine + tenofovir alafenamide

Section	Indications
Fixed-dose combinations of antiretrovirals Oral > Solid: 200 mg + 25 mg + 25 mg	Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Emtricitabine + rilpivirine + tenofovir disoproxil fumarate

Section	Indications
Fixed-dose combinations of antiretrovirals Oral > Solid: 200 mg + 25 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)	Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Emtricitabine + tenofovir

Section	Indications
Fixed-dose combinations of antiretrovirals Oral > Solid: 200 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)	Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified Contact with or exposure to human immunodeficiency virus

Emtricitabine + tenofovir alafenamide

Section	Indications
Fixed-dose combinations of antiretrovirals Oral > Solid: 200 mg + 10 mg; 200 mg + 25 mg	Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Entecavir

Section	Indications
Medicines for hepatitis B > Nucleoside/Nucleotide reverse transcriptase inhibitors Oral > Liquid: 0.05 mg per mL Oral > Solid: 0.5 mg; 1 mg	Chronic hepatitis B

Eravacycline

Section	Indications
Reserve group antibiotics Parenteral > General injections > IV: 50 mg lyophilized powder for injection	Carbapenem resistant Enterobacteriales

Erythromycin

Section	Indications
Watch group antibiotics Parenteral > General injections > IV: 500 mg in vial powder for injection (as lactobionate) Oral > Liquid: 125 mg per 5 mL (as stearate or ethylsuccinate) Oral > Solid: 250 mg (as stearate or ethylsuccinate)	Bacterial infection of unspecified site

Ethambutol

Section	Indications
Antituberculosis medicines Parenteral > General injections > IV: 1000 mg per 10 mL; 2000 mg per 20 mL Oral > Solid: 100 mg (hydrochloride); 400 mg (hydrochloride); 100 mg tablet (dispersible)	Other specified tuberculosis Tuberculosis

Ethambutol + isoniazid

Section	Indications
Antituberculosis medicines Oral > Solid: 400 mg + 150 mg tablet	Tuberculosis

Ethambutol + isoniazid + pyrazinamide + rifampicin

Section	Indications
Antituberculosis medicines Oral > Solid: 275 mg + 75 mg + 400 mg + 150 mg tablet	Tuberculosis

Ethambutol + isoniazid + rifampicin

Section	Indications
Antituberculosis medicines Oral > Solid: 275 mg + 75 mg + 150 mg tablet	Tuberculosis

Ethionamide

Section	Indications
Antituberculosis medicines Oral > Solid: 250 mg tablet; 125 mg tablet (dispersible)	Multi-drug resistant Mycobacterium tuberculosis Tuberculous meningitis

Fexinidazole

Section	Indications
Medicines for the treatment of 1st stage African trypanosomiasis Oral > Solid: 600 mg	African trypanosomiasis
Medicines for the treatment of 2nd stage African trypanosomiasis Oral > Solid: 600 mg	African trypanosomiasis

Fifth generation cephalosporins

Section	Indications
Reserve group antibiotics	Other specified bacterial diseases

Fluconazole

Section	Indications
Antifungal medicines	Cryptococcosis
Parenteral > General injections > IV: 2 mg per mL in vial	Candidosis
Oral > Liquid: 50 mg per 5 mL; 50 mg per 5 mL powder for oral liquid	
Oral > Solid > capsule: 50 mg	

Flucytosine

Section	Indications
Antifungal medicines	Cryptococcosis
Parenteral > General injections > IV: 2.5 g per 250 mL infusion	
Oral > Solid: 250 mg capsule	

Fosfomycin (injection)

Section	Indications
Reserve group antibiotics	Other specified bacterial diseases
Parenteral > General injections > IV: 2 g in vial (as sodium) powder for injection; 4 g in vial (as sodium) powder for injection	Carbapenem resistant Acinetobacter baumannii
	Carbapenem-resistant Pseudomonas aeruginosa
	Carbapenem resistant Enterobacteriales

Fourth generation cephalosporins

Section	Indications
Watch group antibiotics	Other specified bacterial diseases

Gatifloxacin

Section	Indications
Antituberculosis medicines	Multi-drug resistant Mycobacterium tuberculosis
Oral > Solid: 200 mg; 400 mg	

Gentamicin

Section	Indications
Access group antibiotics	
Parenteral > General injections > unspecified: 10 mg per mL in 2 mL vial (as sulfate); 40 mg per mL in 2 mL vial (as sulfate)	First choice Neonatal meningitis co-prescribed with amoxicillin Bacterial pneumonia (Community-acquired pneumonia - severe) [children] co-prescribed with amoxicillin Sepsis without septic shock co-prescribed with ampicillin Acute malnutrition in infants, children or adolescents (complicated) [children] co-prescribed with ampicillin Peritonitis (mild-moderate) co-prescribed with ampicillin Peritonitis (severe) co-prescribed with ampicillin Peritoneal abscess (severe) co-prescribed with ampicillin Sepsis without septic shock co-prescribed with ampicillin Bacterial pneumonia (Community-acquired pneumonia - severe) [children] co-prescribed with ampicillin Peritoneal abscess (mild-moderate) co-prescribed with benzylpenicillin Acute malnutrition in infants, children or adolescents (complicated) [children] co-prescribed with benzylpenicillin Sepsis without septic shock co-prescribed with benzylpenicillin Bacterial pneumonia (Community-acquired pneumonia - severe) [children]
	Second choice Other specified prophylactic measures Gonococcal infection
	Other indications Bacterial infection of unspecified site

Glecaprevir + pibrentasvir

Section	Indications
Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations Oral > Solid: 100 mg + 40 mg tablet; 50 mg + 20 mg granules	Chronic hepatitis C

Griseofulvin

Section	Indications
Antifungal medicines Oral > Liquid: 125 mg per 5 mL Oral > Solid: 125 mg; 250 mg	Dermatophytosis

Hydroxychloroquine

Section	Indications
Antimalarial medicines > For chemoprevention	Therapeutic equivalent to chloroquine for Malaria due to <i>Plasmodium falciparum</i>

Imipenem + cilastatin

Section	Indications
Watch group antibiotics Parenteral > General injections > IV: 250 mg (as monohydrate) + 250 mg (as sodium salt) powder for injection; 500 mg (as monohydrate) + 500 mg (as sodium salt) powder for injection	Second choice Therapeutic equivalent to meropenem for Neutropenia (high-risk) Therapeutic equivalent to meropenem for Peritoneal abscess (severe) Therapeutic equivalent to meropenem for Peritonitis (severe)
Antituberculosis medicines	Other indications Pseudomonas aeruginosa resistant to other antibiotic Antibiotic resistant <i>Acinetobacter baumannii</i>
	Therapeutic equivalent to meropenem for Multi-drug resistant <i>Mycobacterium tuberculosis</i>

Imipenem + cilastatin + relebactam

Section	Indications
Reserve group antibiotics Parenteral > General injections > IV: 500 mg + 500 mg + 250 mg powder for injection	Other specified other antibiotic resistant Enterobacteriales Carbapenem resistant Enterobacteriales Carbapenem-resistant Pseudomonas aeruginosa

Indinavir

Section	Indications
Antiretrovirals > Protease inhibitors Oral > Solid: 400 mg (as sulfate)	Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Isoniazid

Section	Indications
Antituberculosis medicines Parenteral > General injections > IV: 100 mg per mL Oral > Solid: 100 mg tablet; 100 mg tablet (dispersible); 300 mg tablet	Other specified tuberculosis Tuberculosis

Isoniazid + pyrazinamide + rifampicin

Section	Indications
Antituberculosis medicines Oral > Solid: 50 mg + 150 mg + 75 mg tablet (dispersible)	Tuberculosis

Isoniazid + pyridoxine + sulfamethoxazole + trimethoprim

Section	Indications
Medicines for prevention of HIV-related opportunistic infections Oral > Solid: 300 mg + 25 mg + 800 mg + 160 mg tablet (scored)	Other specified prophylactic measures

Isoniazid + rifampicin

Section	Indications
Antituberculosis medicines Oral > Solid: 50 mg + 75 mg tablet (dispersible); 75 mg + 150 mg tablet; 150 mg + 300 mg tablet	Tuberculosis

Isoniazid + rifapentine

Section	Indications
Antituberculosis medicines Oral > Solid: 300 mg + 300 mg tablet (scored)	Latent tuberculosis

Itraconazole

Section	Indications
Antifungal medicines Oral > Liquid: 10 mg per mL Oral > Solid: 100 mg	Chronic pulmonary aspergillosis Chromoblastomycosis Histoplasmosis Talaromycosis Sporotrichosis Paracoccidioidomycosis

Ivermectin

Section	Indications
Intestinal anthelmintics Oral > Solid > tablet: 3 mg	Strongyloidiasis Ascariasis Trichuriasis Hookworm diseases Ancylostomiasis
Antifilarials Oral > Solid > tablet: 3 mg	Onchocerciasis Lymphatic filariasis
Medicines for ectoparasitic infections Oral > Solid > tablet: 3 mg	Scabies

Kanamycin (injection)

Section	Indications
Antituberculosis medicines Parenteral > General injections > IV: 1000 mg powder for injection (vial)	Multi-drug resistant Mycobacterium tuberculosis

Lamivudine

Section	Indications
Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors Oral > Liquid: 50 mg per 5 mL Oral > Solid: 150 mg tablet	Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Lamivudine + nevirapine + zidovudine

Section	Indications
Fixed-dose combinations of antiretrovirals Oral > Solid: 30 mg + 50 mg + 60 mg Tablet; 150 mg + 200 mg + 300 mg Tablet	Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Lamivudine + tenofovir

Section	Indications
Fixed-dose combinations of antiretrovirals	Therapeutic equivalent to emtricitabine + tenofovir for Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
	Therapeutic equivalent to emtricitabine + tenofovir for Contact with or exposure to human immunodeficiency virus

Lamivudine + zidovudine

Section	Indications
Fixed-dose combinations of antiretrovirals Oral > Solid: 30 mg + 60 mg Tablet; 150 mg + 300 mg Tablet	Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Ledipasvir + sofosbuvir

Section	Indications
Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations Oral > Solid: 90 mg + 400 mg tablet	Chronic hepatitis C

Levamisole

Section	Indications
Intestinal anthelmintics Oral > Solid > tablet: 50 mg (as hydrochloride); 150 mg (as hydrochloride)	Ascariasis

Levofloxacin

Section	Indications
<p>Antituberculosis medicines Oral > Solid: 250 mg tablet; 500 mg tablet; 750 mg tablet; 100 mg tablet (dispersible)</p>	Multi-drug resistant Mycobacterium tuberculosis

Linezolid

Section	Indications
<p>Reserve group antibiotics Parenteral > General injections > IV: 2 mg per mL in 300 mL bag Oral > Liquid: 100 mg per 5 mL powder for oral liquid Oral > Solid: 400 mg tablet; 600 mg tablet</p>	Other specified bacterial diseases
<p>Antituberculosis medicines Oral > Solid: 600 mg tablet; 150 mg tablet (dispersible)</p>	Multi-drug resistant Mycobacterium tuberculosis

Lopinavir + ritonavir

Section	Indications
<p>Antiretrovirals > Protease inhibitors Oral > Solid: 100 mg + 25 mg tablet (heat-stable); 200 mg + 50 mg tablet (heat-stable); 40 mg + 10 mg</p>	Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Mebendazole

Section	Indications
<p>Intestinal anthelmintics Oral > Solid > tablet: 100 mg (chewable); 500 mg (chewable)</p>	Ascariasis Enterobiasis Trichuriasis Hookworm diseases
<p>Cysticidal medicines Oral > Solid > tablet: 500 mg (chewable); 100 mg (chewable)</p>	Other specified echinococcosis

Mefloquine

Section	Indications
<p>Antimalarial medicines > For curative treatment Oral > Solid: 250 mg tablet (hydrochloride)</p>	Malaria due to Plasmodium falciparum Malaria due to Plasmodium vivax
<p>Antimalarial medicines > For chemoprevention Oral > Solid: 250 mg tablet (hydrochloride)</p>	Malaria due to Plasmodium falciparum

Meglumine antimoniate

Section	Indications
Antileishmaniasis medicines Parenteral > General injections > IM: 1.5 g per 5 mL in 5 mL ampoule	Visceral leishmaniasis Mucocutaneous leishmaniasis Cutaneous leishmaniasis

Melarsoprol

Section	Indications
Medicines for the treatment of 2nd stage African trypanosomiasis Parenteral > General injections > IV: 3.6% in 5 mL ampoule solution (180 mg of active compound)	African trypanosomiasis

Meropenem

Section	Indications
Watch group antibiotics Parenteral > General injections > IV: 500 mg in vial (as trihydrate) powder for injection; 1 g in vial (as trihydrate) powder for injection	Second choice Neutropenia (high-risk) Peritoneal abscess (severe) Peritonitis (severe) Neonatal meningitis
Antituberculosis medicines Parenteral > General injections > IV: 500 mg in vial (as trihydrate) powder for injection; 1 g in vial (as trihydrate) powder for injection	Multi-drug resistant Mycobacterium tuberculosis

Meropenem + vaborbactam

Section	Indications
Reserve group antibiotics Parenteral > General injections > IV: 1 g in vial + 1 g in vial powder for injection	Carbapenem-resistant <i>Pseudomonas aeruginosa</i> Carbapenem resistant <i>Enterobacteriales</i> Carbapenem resistant <i>Acinetobacter baumannii</i>

Metronidazole

Section	Indications
Access group antibiotics Oral > Liquid: 200 mg per 5 mL (as benzoate) Oral > Solid: 200 to 500 mg tablet Parenteral > General injections > unspecified: 500 mg per 100 mL in vial Injection Local > Rectal > Suppository: 500 mg suppository; 1 g suppository	First choice co-prescribed with cefazolin Other specified prophylactic measures co-prescribed with cefotaxime Peritoneal abscess (severe) co-prescribed with cefotaxime Peritonitis (mild-moderate) co-prescribed with cefotaxime Peritoneal abscess (mild-moderate) co-prescribed with cefotaxime Peritonitis (severe) co-prescribed with ceftriaxone Peritoneal abscess (severe) co-prescribed with ceftriaxone Peritoneal abscess (mild-moderate) co-prescribed with ceftriaxone Peritonitis (mild-moderate) co-prescribed with ceftriaxone Peritonitis (severe) Second choice co-prescribed with ciprofloxacin Peritoneal abscess (mild-moderate) co-prescribed with ciprofloxacin Peritonitis (mild-moderate) Other indications Bacterial infection of unspecified site Amoebiasis
Antiamoebic and antigiardiasis medicines Oral > Liquid: 200 mg per 5 mL (as benzoate) Parenteral > General injections > unspecified: 500 mg in 100 mL vial Oral > Solid > tablet: 200 mg; 250 mg; 400 mg; 500 mg	

Micafungin

Section	Indications
Antifungal medicines Parenteral > General injections > IV: 50 mg in vial (as sodium) powder for injection; 100 mg in vial (as sodium) powder for injection	Systemic or invasive candidosis

Miltefosine

Section	Indications
Antileishmaniasis medicines Oral > Solid: 10 mg; 50 mg	Visceral leishmaniasis Mucocutaneous leishmaniasis Cutaneous leishmaniasis

Moxifloxacin

Section	Indications
Antituberculosis medicines Oral > Solid: 400 mg tablet; 100 mg tablet (dispersible) Oral > Solid: 400 mg tablet	Multi-drug resistant Mycobacterium tuberculosis Tuberculosis

Nalidixic acid

Section	Indications
Anti-infective medicines Oral > Solid: 250 mg; 500 mg	Shigella resistant to unspecified antibiotic

Nelfinavir

Section	Indications
Antiretrovirals > Protease inhibitors Oral > Solid: 250 mg (as mesilate) Oral > Other: 50 mg per g oral powder	Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Nevirapine

Section	Indications
Antiretrovirals > Non-nucleoside reverse transcriptase inhibitors Oral > Liquid: 50 mg per 5 mL oral solution Oral > Solid: 200 mg tablet; 50 mg tablet (dispersible)	Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Niclosamide

Section	Indications
Intestinal anthelmintics Oral > Solid: 500 mg tablet (chewable)	Hymenolepasis Diphyllobothriasis Taeniasis due to Taenia saginata Taeniasis due to Taenia solium

Nifurtimox

Section	Indications
Medicines for the treatment of 2nd stage African trypanosomiasis Oral > Solid > tablet: 120 mg (scored); 30 mg (scored)	African trypanosomiasis
American trypanosomiasis Oral > Solid > tablet: 30 mg (scored); 120 mg (scored)	Chagas disease

Nystatin

Section	Indications
Antifungal medicines Oral > Liquid: 100000 IU per mL Local > Topical > Other: 100000 IU pessary Oral > Solid > dosage form: 500000 IU Oral > Solid > lozenge: 100000 IU	Candidosis

Ofloxacin

Section	Indications
Antituberculosis medicines Oral > Solid: 200 mg; 400 mg	Multi-drug resistant Mycobacterium tuberculosis

Omadacycline

Section	Indications
Reserve group antibiotics Parenteral > General injections > IV: 100 mg lyophilized powder for injection Oral > Solid: 300 mg	Methicillin resistant <i>Staphylococcus aureus</i>

Ombitasvir + paritaprevir + ritonavir

Section	Indications
Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations Oral > Solid: 12.5 mg + 75 mg + 50 mg tablet	Chronic hepatitis C

Oseltamivir

Section	Indications
Other antivirals Oral > Solid: 30 mg capsule (as phosphate); 45 mg capsule (as phosphate); 75 mg capsule (as phosphate)	Influenza due to identified seasonal influenza virus

Oxamniquine

Section	Indications
Antischistosomals and other antitrematode medicines Oral > Liquid: 250 mg per 5 mL Oral > Solid: 250 mg capsule	Schistosomiasis due to <i>Schistosoma mansoni</i>

Oxazolidinones

Section	Indications
Reserve group antibiotics	Other specified bacterial diseases

P-aminosalicylate sodium

Section	Indications
Antituberculosis medicines Oral > Liquid: 5.52 g in sachet (equivalent to 4 g p-aminosalicylic acid)	Multi-drug resistant <i>Mycobacterium tuberculosis</i>

P-aminosalicylic acid

Section	Indications
Antituberculosis medicines Oral > Solid: 4 g granules in sachet	Multi-drug resistant <i>Mycobacterium tuberculosis</i>

Paromomycin

Section	Indications
Antileishmaniasis medicines Parenteral > General injections > IM: 750 mg paromomycin base (as sulfate)	Visceral leishmaniasis
Antiamoebic and antigiardiasis medicines Oral > Liquid: 125 mg per 5 mL as sulfate Oral > Solid: 250 mg as sulfate	Amoebiasis

Pegylated interferon alfa (2a)

Section	Indications
Medicines for hepatitis C > Other antivirals for hepatitis C Parenteral > General injections > SC: 180 µg in vial; 180 µg in prefilled syringe	Chronic hepatitis C

Pegylated interferon alfa (2b)

Section	Indications
Medicines for hepatitis C > Other antivirals for hepatitis C Parenteral > General injections > SC: 80 µg in prefilled syringe; 100 µg in prefilled syringe	Chronic hepatitis C

Pentamidine

Section	Indications
Antileishmaniasis medicines Parenteral > General injections > IM: 200 mg (as isetionate); 300 mg (as isetionate)	Visceral leishmaniasis
Antipneumocystosis and antitoxoplasmosis medicines Oral > Solid: 200 mg tablet; 300 mg tablet	Pneumocystosis
Medicines for the treatment of 1st stage African trypanosomiasis Parenteral > General injections > IM: 300 mg in vial (as isetionate) powder for injection	African trypanosomiasis

Phenoxymethylenicillin

Section	Indications
Access group antibiotics Oral > Liquid: 250 mg per 5 mL (as potassium salt) powder for oral liquid	First choice
Oral > Solid: 250 mg (as potassium salt) tablet	Acute pharyngitis
Oral > Solid: 250 mg (as potassium salt); 500 mg (as potassium salt)	Periapical abscess without sinus
	Bacterial pneumonia (Community-acquired pneumonia - mild to moderate)
	Other indications
	Bacterial infection of unspecified site

Piperacillin + tazobactam

Section	Indications
Watch group antibiotics Parenteral > General injections > IV: 2 g (as sodium salt) + 250 mg (as sodium salt) powder for injection; 4 g (as sodium salt) + 500 mg (as sodium salt) powder for injection	First choice
	Peritoneal abscess (severe)
	Neutropenia (high-risk)
	Peritonitis (severe)
	Other specified pneumonia (Hospital-acquired pneumonia)

Plazomicin

Section	Indications
Reserve group antibiotics Parenteral > General injections > IV: 500 mg per 10 mL (Injection)	Carbapenem resistant <i>Acinetobacter baumannii</i> Carbapenem-resistant <i>Pseudomonas aeruginosa</i> Carbapenem resistant <i>Enterobacteriales</i>

Polymyxins

Section	Indications
Reserve group antibiotics	Other specified bacterial diseases

Potassium iodide

Section	Indications
Antifungal medicines Local > Topical > Solution: Saturated solution	Sporotrichosis

Praziquantel

Section	Indications
Antischistosomals and other antitrematode medicines Oral > Solid > tablet: 600 mg (scored); 500 mg; 150 mg	Paragonimiasis Clonorchiasis Opisthorchiasis Schistosomiasis
Intestinal anthelmintics Oral > Solid > tablet: 600 mg (scored); 500 mg; 150 mg	Taeniasis due to <i>Taenia saginata</i> Taeniasis due to <i>Taenia solium</i> Diphyllobothriasis Hymenolepasis
Cysticidal medicines Oral > Solid > tablet: 600 mg (scored); 500 mg; 150 mg	Cysticercosis of central nervous system

Pretomanid

Section	Indications
Antituberculosis medicines Oral > Solid > tablet: 200 mg	Multi-drug resistant <i>Mycobacterium tuberculosis</i>

Primaquine

Section	Indications
Antimalarial medicines > For curative treatment Oral > Solid: 7.5 mg tablet (as phosphate); 15 mg tablet (as phosphate)	Malaria due to <i>Plasmodium ovale</i> Malaria due to <i>Plasmodium vivax</i>

Procaine benzylpenicillin

Section	Indications
Access group antibiotics Parenteral > General injections > IM: 1 g in vial (=1 million IU) powder for injection; 3 g in vial (=3 million IU) powder for injection	First choice Congenital syphilis [children] Second choice Syphilis

Proguanil

Section	Indications
Antimalarial medicines > For chemoprevention Oral > Solid: 100 mg tablet (hydrochloride)	Malaria due to <i>Plasmodium falciparum</i>

Protonamide

Section	Indications
Antituberculosis medicines	Therapeutic equivalent to ethionamide for Multi-drug resistant <i>Mycobacterium tuberculosis</i>

Pyrantel

Section	Indications
Intestinal anthelmintics Oral > Solid > tablet: 250 mg (chewable) (as embonate or pamoate)	Ascariasis Enterobiasis Trichuriasis Hookworm diseases

Pyrazinamide

Section	Indications
Antituberculosis medicines Oral > Solid: 400 mg; 150 mg tablet (dispersible); 500 mg	Tuberculosis

Pyrimethamine

Section	Indications
Antipneumocystosis and antitoxoplasmosis medicines Oral > Solid: 25 mg	Toxoplasmosis

Quinine

Section	Indications
Antimalarial medicines > For curative treatment Parenteral > General injections > IV: 300 mg per mL in 2 mL ampoule (quinine hydrochloride) Oral > Solid: 300 mg (quinine sulfate or quinine bisulfate)	Malaria due to <i>Plasmodium falciparum</i>

Raltegravir

Section	Indications
Antiretrovirals > Integrase inhibitors Oral > Liquid: 100 mg granules for oral suspension Oral > Solid: 400 mg tablet; 25 mg tablet (chewable)	Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Ravidasvir

Section	Indications
Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations Oral > Solid > tablet: 200 mg	Chronic hepatitis C

Ribavirin

Section	Indications
Other antivirals Parenteral > General injections > IV: 1000 mg per 10 mL phosphate buffer solution; 800 mg per 10 mL phosphate buffer solution Oral > Solid: 200 mg; 400 mg; 600 mg	Viral haemorrhagic fever, not elsewhere classified
Medicines for hepatitis C > Other antivirals for hepatitis C Parenteral > General injections > IV: 1000 mg per 10 mL phosphate buffer solution; 800 mg per 10 mL phosphate buffer solution Oral > Solid: 200 mg; 400 mg; 600 mg	Chronic hepatitis C

Rifabutin

Section	Indications
Antituberculosis medicines Oral > Solid: 150 mg	Tuberculosis

Rifampicin

Section	Indications
Antituberculosis medicines	Tuberculosis
Oral > Liquid: 20 mg per mL	Other specified tuberculosis
Oral > Solid: 150 mg; 300 mg	
Parenteral > General injections > IV: 600 mg in vial powder for injection	
Antileprosy medicines	Leprosy
Oral > Liquid: 20 mg per mL	
Oral > Solid: 150 mg; 300 mg	

Rifapentine

Section	Indications
Antituberculosis medicines	Tuberculosis
Oral > Solid: 150 mg tablet; 300 mg tablet	Latent tuberculosis

Ritonavir

Section	Indications
Antiretrovirals > Protease inhibitors Oral > Solid: 25 mg tablet (heat stable); 100 mg tablet (heat stable)	Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Saquinavir

Section	Indications
Antiretrovirals > Protease inhibitors Oral > Solid: 200 mg; 500 mg	Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Simeprevir

Section	Indications
Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations Oral > Solid: 150 mg	Chronic hepatitis C

Sodium stibogluconate

Section	Indications
Antileishmaniasis medicines Parenteral > General injections > unspecified: 100 mg per mL in 30 mL vial	Visceral leishmaniasis Mucocutaneous leishmaniasis Cutaneous leishmaniasis

Sofosbuvir

Section	Indications
Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations Oral > Solid: 400 mg; 200 mg	Chronic hepatitis C

Sofosbuvir + velpatasvir

Section	Indications
Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations Oral > Solid: 400 mg + 100 mg tablet; 200 mg + 50 mg tablet	Chronic hepatitis C

Spectinomycin

Section	Indications
Access group antibiotics Parenteral > General injections > unspecified: 2 g in vial (as hydrochloride) powder for injection	Second choice Gonococcal infection
	Other indications Bacterial infection of unspecified site

Stavudine

Section	Indications
Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors Oral > Liquid: 5 mg per 5 mL powder for oral solution Oral > Solid: 15 mg; 20 mg; 30 mg	Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Streptomycin (injection)

Section	Indications
Antituberculosis medicines Parenteral > General injections > IV: 1 g powder for injection (as sulfate) as vial	Multi-drug resistant Mycobacterium tuberculosis

Sulfadiazine

Section	Indications
Antipneumocystosis and antitoxoplasmosis medicines Oral > Solid: 500 mg	Toxoplasmosis
Anti-infective medicines Oral > Solid: 500 mg Parenteral > General injections > unspecified: 250 mg in 4 mL ampoule (sodium salt)	Bacterial infection of unspecified site

Sulfadimidine

Section	Indications
Anti-infective medicines Oral > Liquid: 500 mg per 5 mL	Bacterial infection of unspecified site
Oral > Solid: 500 mg Parenteral > General injections > unspecified: 1 g in 3 mL ampoule (sodium salt)	

Sulfadoxine + pyrimethamine

Section	Indications
Antimalarial medicines > For curative treatment Oral > Solid: 500 mg + 25 mg tablet	Malaria due to Plasmodium falciparum Malaria due to Plasmodium vivax
Antimalarial medicines > For chemoprevention Oral > Solid: 500 mg + 25 mg tablet	Malaria due to Plasmodium falciparum
Oral > Solid: 250 mg + 12.5 mg tablet	Malaria

Sulfamethoxazole + trimethoprim

Section	Indications
<p>Access group antibiotics</p> <p>Parenteral > General injections > IV: 80 mg + 16 mg per mL in 10 mL ampoule; 80 mg + 16 mg per mL in 5 mL ampoule</p> <p>Oral > Liquid: 200 mg + 40 mg per 5 mL oral liquid</p> <p>Oral > Solid: 100 mg + 20 mg tablet; 400 mg + 80 mg tablet; 800 mg + 160 mg tablet</p>	Bacterial infection of unspecified site
<p>Antipneumocystosis and antitoxoplasmosis medicines</p> <p>Parenteral > General injections > IV: 80 mg + 16 mg per mL in 5 mL ampoule; 80 mg + 16 mg per mL in 10 mL ampoule</p> <p>Oral > Liquid: 200 mg + 40 mg per 5 mL oral liquid</p> <p>Oral > Solid: 100 mg + 20 mg tablet; 400 mg + 80 mg tablet; 800 mg + 160 mg tablet</p> <p>Oral > Solid > dispersible tablet: 100 mg + 20 mg</p>	Pneumocystosis

Suramin sodium

Section	Indications
<p>Antifilarials</p> <p>Parenteral > General injections > IV: 1 g in vial</p>	Filariasis
<p>Medicines for the treatment of 1st stage African trypanosomiasis</p> <p>Parenteral > General injections > IV: 1 g in vial</p>	African trypanosomiasis

Tenofovir alafenamide

Section	Indications
<p>Medicines for hepatitis B > Nucleoside/Nucleotide reverse transcriptase inhibitors</p> <p>Oral > Solid: 25 mg</p>	Chronic hepatitis B

Tenofovir disoproxil fumarate

Section	Indications
<p>Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors</p> <p>Oral > Solid: 300 mg tablet (equivalent to 245 mg tenofovir disoproxil)</p>	Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
<p>Medicines for hepatitis B > Nucleoside/Nucleotide reverse transcriptase inhibitors</p> <p>Oral > Solid: 300 mg tablet (equivalent to 245 mg tenofovir disoproxil)</p>	Contact with or exposure to human immunodeficiency virus
	Chronic hepatitis B

Terizidone

Section	Indications
Antituberculosis medicines	Therapeutic equivalent to cycloserine for Multi-drug resistant Mycobacterium tuberculosis

Tetracycline

Section	Indications
Access group antibiotics Oral > Solid: 250 mg (hydrochloride)	Bacterial infection of unspecified site

Tigecycline

Section	Indications
Reserve group antibiotics Parenteral > General injections > IV: 50 mg in vial powder for injection	Other specified bacterial diseases

Tinidazole

Section	Indications
Antiamoebic and antigiardiasis medicines	Therapeutic equivalent to metronidazole for Amoebiasis

Triclabendazole

Section	Indications
Antischistosomals and other antitrematode medicines Oral > Solid > tablet: 250 mg (scored)	Fascioliasis Paragonimiasis

Trimethoprim

Section	Indications
Access group antibiotics Oral > Liquid: 50 mg per mL Oral > Solid: 100 mg; 200 mg	First choice Infectious cystitis

Valaciclovir

Section	Indications
Antiherpes medicines	Therapeutic equivalent to aciclovir for Zoster Therapeutic equivalent to aciclovir for Varicella Therapeutic equivalent to aciclovir for Herpes simplex infections

Valganciclovir

Section	Indications
Other antivirals Oral > Liquid: 50 mg per mL powder for oral solution Oral > Solid: 450 mg Tablet	Cytomegaloviral retinitis

Vancomycin

Section	Indications
Watch group antibiotics Parenteral > General injections > IV: 250 mg in vial (as hydrochloride) powder for injection	First choice co-prescribed with ceftazidime Endophthalmitis co-prescribed with ceftriaxone Endophthalmitis Other indications Methicillin resistant Staphylococcus aureus

Voriconazole

Section	Indications
Antifungal medicines Parenteral > General injections > IV: 200 mg in vial powder for injection Oral > Liquid: 40 mg per mL powder for oral liquid Oral > Solid: 50 mg tablet; 200 mg tablet	Chronic pulmonary aspergillosis Invasive aspergillosis

Zidovudine

Section

Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors
Parenteral > General injections > IV: 10 mg per mL in 20 mL vial solution
for IV infusion injection
Oral > Liquid: 50 mg per 5 mL
Oral > Solid: 250 mg capsule; 300 mg tablet

Indications

Human immunodeficiency virus disease
without mention of associated disease or
condition, clinical stage unspecified